Antibiotic Resistance Is the Quiet Public-Health Emergency
Resistant infections kill more people yearly than road accidents, and the R&D pipeline for new antibiotics is nearly empty.
0 reactions · anonymous
An innovation-market failure
Antibiotics are used briefly and priced cheaply, so pharma has little incentive to develop them — a market failure with lethal consequences.
Push-pull mechanisms like subscription payments are finally funding the pipeline, but stewardship (using less) and new classes must arrive before the last lines of defence fail.
Building incoffeed — a daily editorial on tech, AI, fintech and business. Co-founder & editor.
Discussion
0// No comments yet — be the first to start the discussion.
